Valeant to sell off $2B in assets to ease debt: 3 takeaways

Valeant Pharmaceuticals entered into two separate deals to sell off its oncology division and skin care unit for more than $2 billion, reports Bloomberg.

Here are three things to know.

1. The Paris-based cosmetics company L'Oreal will pay $1.3 billion for Valeant's three over-the-counter skin care brands: CerAve, AcneFree and Ambi. The three brands have combined annual sales of $168 million.

2. The Chinese conglomerate Sanpower Group will acquire Valeant's cancer drug unit, Dendreon Pharmaceuticals, for $820 million. Valeant acquired Dendreon for $445 million in 2015.

3. The deals represent Valeant's largest divestitures in almost three years and will help decrease the drugmaker's $30 billion debt pile, according to Bloomberg.

More articles on supply chain:

Naloxone now available free-of-charge for at-risk youth in Oklahoma
St. Jude Medical releases cybersecurity updates for vulnerable heart devices
Egalet earns FDA approval for abuse-deterrent opioid painkiller


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars